Novo Nordisk A/S (NYSE:NVO) Shares Sold by Integrated Advisors Network LLC

Integrated Advisors Network LLC decreased its position in Novo Nordisk A/S (NYSE:NVO) by 69.2% in the 4th quarter, Holdings Channel.com reports. The firm owned 3,791 shares of the company’s stock after selling 8,536 shares during the period. Integrated Advisors Network LLC’s holdings in Novo Nordisk A/S were worth $326,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors also recently made changes to their positions in the company. GQG Partners LLC grew its holdings in Novo Nordisk A/S by 74.7% in the 4th quarter. GQG Partners LLC now owns 12,994,533 shares of the company’s stock worth $1,117,790,000 after buying an additional 5,556,460 shares in the last quarter. Raymond James Financial Inc. acquired a new position in Novo Nordisk A/S during the 4th quarter worth $404,910,000. Loomis Sayles & Co. L P grew its stake in shares of Novo Nordisk A/S by 34.2% in the fourth quarter. Loomis Sayles & Co. L P now owns 11,571,686 shares of the company’s stock worth $995,397,000 after purchasing an additional 2,947,771 shares in the last quarter. Nuveen Asset Management LLC increased its holdings in shares of Novo Nordisk A/S by 73.2% during the fourth quarter. Nuveen Asset Management LLC now owns 6,244,931 shares of the company’s stock valued at $537,189,000 after purchasing an additional 2,639,693 shares during the period. Finally, Two Sigma Investments LP acquired a new stake in Novo Nordisk A/S in the fourth quarter worth about $158,657,000. Institutional investors and hedge funds own 11.54% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts have commented on the stock. BMO Capital Markets reissued a “market perform” rating and set a $64.00 target price (down previously from $105.00) on shares of Novo Nordisk A/S in a research note on Thursday, April 17th. Wall Street Zen upgraded shares of Novo Nordisk A/S from a “buy” rating to a “strong-buy” rating in a research note on Friday, April 25th. Kepler Capital Markets upgraded Novo Nordisk A/S from a “hold” rating to a “buy” rating in a research report on Thursday, March 13th. Guggenheim lowered Novo Nordisk A/S from a “strong-buy” rating to a “hold” rating in a research note on Thursday, April 17th. Finally, BNP Paribas assumed coverage on Novo Nordisk A/S in a research note on Tuesday, April 15th. They issued an “underperform” rating on the stock. Two analysts have rated the stock with a sell rating, five have assigned a hold rating, five have given a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat.com, Novo Nordisk A/S has a consensus rating of “Moderate Buy” and an average target price of $135.00.

Novo Nordisk A/S Price Performance

Shares of NYSE:NVO opened at $68.64 on Thursday. The company has a market capitalization of $308.02 billion, a PE ratio of 20.86, a price-to-earnings-growth ratio of 0.90 and a beta of 0.65. The company has a debt-to-equity ratio of 0.62, a quick ratio of 0.55 and a current ratio of 0.74. The stock has a fifty day moving average of $65.74 and a 200-day moving average of $82.29. Novo Nordisk A/S has a one year low of $57.00 and a one year high of $148.15.

Novo Nordisk A/S (NYSE:NVO) last announced its earnings results on Wednesday, May 7th. The company reported $0.92 EPS for the quarter, meeting the consensus estimate of $0.92. The business had revenue of $11.87 billion during the quarter. Novo Nordisk A/S had a return on equity of 84.68% and a net margin of 34.81%. As a group, equities analysts anticipate that Novo Nordisk A/S will post 3.84 EPS for the current fiscal year.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.